ME01344B - Upotreba derivata benzo-kondenziranih heterocikličkih sulfamida za liječenje gojaznosti - Google Patents
Upotreba derivata benzo-kondenziranih heterocikličkih sulfamida za liječenje gojaznostiInfo
- Publication number
- ME01344B ME01344B MEP-2011-166A MEP16611A ME01344B ME 01344 B ME01344 B ME 01344B ME P16611 A MEP16611 A ME P16611A ME 01344 B ME01344 B ME 01344B
- Authority
- ME
- Montenegro
- Prior art keywords
- benzo
- dihydro
- group
- dioxynyl
- lower alkyl
- Prior art date
Links
- -1 heterocycle sulfamide derivatives Chemical class 0.000 title claims 6
- 208000008589 Obesity Diseases 0.000 title claims 4
- 235000020824 obesity Nutrition 0.000 title claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- KXSAIQPPGSSNKX-ZETCQYMHSA-N (2s)-6-chloro-2-[(sulfamoylamino)methyl]-2,3-dihydro-1,4-benzodioxine Chemical compound ClC1=CC=C2O[C@@H](CNS(=O)(=O)N)COC2=C1 KXSAIQPPGSSNKX-ZETCQYMHSA-N 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 230000001737 promoting effect Effects 0.000 claims 3
- 230000004580 weight loss Effects 0.000 claims 3
- 230000036528 appetite Effects 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000003880 negative regulation of appetite Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
Claims (10)
1.Spoj formule (I): ili njegova farmaceutski prihvatljiva sol za upotrebu kod liječenja pretilosti, poticanje gubitka težine ili suzbijanje apetita naznačen time da: R1 iR2 su svaki nezavisno odabrani iz skupine koju čine vodik i niži alkil; R4 je odabran iz skupine koju sačinjavaju vodik i niži alkil; a je cijeli broj od 1 do 2; pri čemu b je cijeli broj od 0 do 4; i gdje a je cijeli broj od 0 do 2; svaki R5 je nezavisno odabran iz skupine koja sadrži halogen i niži alkil; pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika, pod uvjetom da kada je ili tada a je 1.
2.Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time da: R1 i R2 su svaki nezavisno odabrani iz skupine koju čine vodik i niži alkil; R4 je odabran iz skupine koju sačinjavaju vodik i niži alkil; a je cijeli broj od 1 do 2; gdje je cijeli broj od 0 do 2; gdje c je cijeli broj od 0 do 1; svaki R5 je Nezavisno odabran iz skupine koja sadrži halogen i niži alkil; pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika, pod uvjetom da kada ili tada a je 1.
3.Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 2, naznačen time da: R1 i R2 su svaki nezavisno odabrani iz skupine koju čine vodik i niži alkil; R1 je odabran iz skupine koju sačinjavaju vodik i niži alkil; a je cijeli broj od 1 do 2; pri čemu bje cijeli broj od 0 do 2; i pri čemu c je 0; svaki R6 je nezavisno odabran iz skupine koja sadrži halogen i niži alkil; pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika pod uvjetom da kada tada a je 1.
4. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 3 naznačen time da: R1 i R2 su svaki nezavisno odabrani iz skupine koja sadrži vodik i niži alkil; R4 je odabran iz skupine koju sačinjavaju vodik i metil; a je cijeli broj od 1 do 2: je odabran iz skupine koju sačinjavaju 2-(2,3-dihidrobenzo[l,4]dioksinil), 2- (benzo[l,3]dioksolil), 2-(3,4-dihidro-2H-benzo[l,4]dioksepinil), 2-(8-kloro-2,3- dihidro-benzo[l,4]dioksinil), 2-(6-fluoro-2,3-dihidro-benzo[l,4]dioksinil), 2- (kromanil), 2-(6-fluoro-2,3-dihidro-benzo[ 1,4]dioksinil), 2-(7-kloro-2,3-dihidro- benzo[l,4]dioksinil), 2-(6-kloro-benzo[l,3]dioksolil), 2-(7-metil-2,3-dihidro- benzo[ 1,4]dioksinil), 2-(5-kloro-2,3-dihidro-benzo[ 1,4]dioksinil), 2-(6-bromo-2,3- dihidro-benzo[l,4]dioksinil), 2-(6,7-dikloro-2,3-dihidro-benzo[l,4]dioksinil), 2-(8- kloro-2,3-dihidro-benzo[l,4]dioksinil), 2-(2,3-dihidro-nafto[2,3-b][l,4]dioksinil) i 2- (4-metil-benzo[l,3]dioksolil);pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika, pod uvjetom da kada je 2-(3,4-dihidro-2H-benzo[l,4]dioksepinil), tada a je 1.
5. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 4 naznačen time da: R1 i R2 su svaki nezavisno odabrani iz skupine koja sadrži vodik i metil; R4 je odabran iz skupine koja sadrži vodik i metil; a je cijeli broj od 1 do 2; je odabran iz skupine koju sačinjavaju 2-benzo[l,3]dioksolil), 2-(2,3-dihidro- benzo[l,4]dioksinil), 2-(6-kloro-2,3- dihidro-benzo[l,4]dioksinil), 2-(7-kloro-2,3- dihidro-benzo[l,4]dioksinil), 2-(7-metil-2,3-dihidro-benzo[l,4]dioksinil), 2-(6-bromo- 2,3-dihidrobenzo[l,4]dioksinil) i 2-(6,7-dikloro-2,3-dihidro-benzo[l,4]dioksinil).
6.Spoj prema zahtjevu 1, naznačen time daje spoj prema formuli (I) odabran iz skupine koju čine (2S)-(-)-N-(6-kloro-2,3-dihidrobenzo[l,4]dioksin-2-ilmetil)-sulfamido; i njegove farmaceutski prihvatljive soli.
7.Spoj naznačen time da je odabran iz skupine koju čine (2S)-(-)-N-(6-kloro-2,3-dihidro- benzo[l,4]dioksin-2-ilmetil)-sulfamid; i njegove farmaceutski prihvatljive soli za uporabu kod liječenja pretilosti.
8.Spoj naznačen time da je odabran iz skupine koju čine (2S)-(-)-N-(6-kloro-2,3-dihidro- benzo[l,4]dioksin-2-ilmetil)-sulfamid; i njegove farmaceutski prihvatljive soli za uporabu kod poticanja gubitka težine.
9.Spoj naznačen time da je odabran iz skupine koju čine (2S)-(-)-N-(6-kloro-2,3-dihidro- benzol[l,4]dioksin-2-ilmetil)-sulfamid; i njegove farmaceutski prihvatljive soli za uporabu kod suzbijanja apetita.
10.Spoj formule (II) ili njegova farmaceutski prihvatljiva sol naznačen time daje za upotrebu kod liječenja pretilosti, poticanje gubitka težine ili suzbijanje apetita.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75149905P | 2005-12-19 | 2005-12-19 | |
| US11/611,938 US8492431B2 (en) | 2005-12-19 | 2006-12-18 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
| PCT/US2006/048681 WO2007075833A2 (en) | 2005-12-19 | 2006-12-19 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
| EP06847860A EP1968574B9 (en) | 2005-12-19 | 2006-12-19 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01344B true ME01344B (me) | 2013-12-20 |
Family
ID=37992995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2011-166A ME01344B (me) | 2005-12-19 | 2006-12-19 | Upotreba derivata benzo-kondenziranih heterocikličkih sulfamida za liječenje gojaznosti |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8492431B2 (me) |
| EP (1) | EP1968574B9 (me) |
| JP (1) | JP5190378B2 (me) |
| KR (1) | KR101363308B1 (me) |
| CN (1) | CN101365442B (me) |
| AR (1) | AR058389A1 (me) |
| AT (1) | ATE519484T1 (me) |
| AU (1) | AU2006331637B2 (me) |
| BR (1) | BRPI0620019A2 (me) |
| CA (1) | CA2634093C (me) |
| CR (1) | CR10164A (me) |
| CY (1) | CY1112357T1 (me) |
| DK (1) | DK1968574T3 (me) |
| EA (1) | EA016560B1 (me) |
| ES (1) | ES2369761T3 (me) |
| HR (1) | HRP20110726T2 (me) |
| IL (1) | IL192107A (me) |
| ME (1) | ME01344B (me) |
| MY (1) | MY145823A (me) |
| NO (1) | NO20083006L (me) |
| NZ (1) | NZ568960A (me) |
| PE (1) | PE20070813A1 (me) |
| PL (1) | PL1968574T3 (me) |
| PT (1) | PT1968574E (me) |
| RS (1) | RS52044B (me) |
| SI (1) | SI1968574T1 (me) |
| SV (1) | SV2008002952A (me) |
| UY (1) | UY30033A1 (me) |
| WO (1) | WO2007075833A2 (me) |
| ZA (1) | ZA200806279B (me) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| MX2007014613A (es) * | 2005-05-20 | 2008-04-02 | Johnson & Johnson | Procedimiento para la preparacion de derivados de sulfamida. |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| AR058389A1 (es) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
| WO2007137167A2 (en) | 2006-05-19 | 2007-11-29 | Janssen Pharmaceutica N.V. | Co-therapy for the treatment of epilepsy |
| US20090247616A1 (en) * | 2008-03-26 | 2009-10-01 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety |
| KR20100135325A (ko) | 2008-04-29 | 2010-12-24 | 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 | 도파민 신경전달의 조절제 |
| AU2009242095A1 (en) * | 2008-04-29 | 2009-11-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
| EP2271635A1 (en) * | 2008-04-29 | 2011-01-12 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | Modulators of dopamine neurotransmission |
| AU2009271362B2 (en) | 2008-06-23 | 2014-03-13 | Janssen Pharmaceutica Nv | Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
| US8815939B2 (en) * | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| US8895762B2 (en) | 2011-09-29 | 2014-11-25 | Janssen Pharmaceutica Nv | Process for the preparation of sulfamide derivatives |
| AU2012316279A1 (en) | 2011-09-29 | 2014-04-17 | Janssen Pharmaceutica Nv | Process for the preparation of sulfamide derivatives |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2527861A (en) | 1948-05-07 | 1950-10-31 | Monsanto Chemicals | Mono alkyl sulfamides |
| BE636655A (me) | 1962-09-14 | |||
| DE1211166B (de) | 1962-11-20 | 1966-02-24 | Ciba Geigy | Verfahren zur Herstellung neuer Sulfamide |
| US3320314A (en) | 1964-01-22 | 1967-05-16 | Sandoz Ag | Chlorobenzyl sulfamides |
| US3318952A (en) | 1964-01-22 | 1967-05-09 | Sandoz Ag | Dibenzylsulfamides |
| US3383414A (en) | 1964-08-26 | 1968-05-14 | Sandoz Ag | Benzocycloalkyl sulfamides |
| DE1542785A1 (de) | 1965-07-24 | 1970-05-06 | Bayer Ag | Insekten- und milbenabweisende Mittel |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| US3621096A (en) | 1969-04-03 | 1971-11-16 | Univ North Carolina | Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone |
| DE2022370A1 (de) | 1970-05-08 | 1971-12-02 | Bayer Ag | N-Fluordichlormethylthio-sulfamidsaeure-Derivate,Verfahren zu ihrer Herstellung und ihre mikrobizide und fungizide Verwendung |
| US5212326A (en) | 1979-08-20 | 1993-05-18 | Abbott Laboratories | Sodium hydrogen divalproate oligomer |
| FR2479825A1 (fr) | 1980-04-04 | 1981-10-09 | Fabre Sa Pierre | Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments |
| US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| US5238945A (en) | 1989-04-11 | 1993-08-24 | H. Lundbeck A/S | Method of treating psychoses |
| GB8908085D0 (en) | 1989-04-11 | 1989-05-24 | Lundbeck & Co As H | New therapeutic use |
| US5273993A (en) | 1989-06-12 | 1993-12-28 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals |
| US5194446A (en) | 1989-06-12 | 1993-03-16 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals |
| US5192785A (en) | 1989-09-03 | 1993-03-09 | A. H. Robins Company, Incorporated | Sulfamates as antiglaucoma agents |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5189179A (en) | 1990-08-29 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | Serotonin 5ht1a agonists |
| CA2054339C (en) | 1990-11-02 | 2002-12-24 | Francesco G. Salituro | 3-amidoindolyl derivatives |
| GB9026998D0 (en) | 1990-12-12 | 1991-01-30 | Glaxo Group Ltd | Medicaments |
| US5120758A (en) | 1991-02-08 | 1992-06-09 | Ciba-Geigy Corporation | Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors |
| GB9104890D0 (en) | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
| IL103172A (en) | 1991-09-19 | 1997-01-10 | Mcneilab Inc | Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol |
| US5242942A (en) | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
| US5258402A (en) | 1992-06-11 | 1993-11-02 | Mcneil-Ppc, Inc. | Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| US5384327A (en) | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
| NZ277725A (en) | 1993-12-23 | 1998-04-27 | Ortho Pharma Corp | Pseudofructopyranose sulphamate derivatives, preparation and pharmaceutical compositions thereof |
| GB9417532D0 (en) | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
| CA2216648A1 (en) | 1995-02-15 | 1996-08-22 | Bearsden Bio, Inc. | Alkylcarboxy amino acids-modulators of the kainate receptor |
| JP3235448B2 (ja) | 1995-03-24 | 2001-12-04 | ダイソー株式会社 | １，４−ベンゾジオキサン誘導体の製法 |
| US5998380A (en) | 1995-10-13 | 1999-12-07 | New England Medical Center Hospitals, Inc. | Treatment of migraine |
| AU7655796A (en) | 1995-11-30 | 1997-06-19 | C & C Research Laboratories | Sulfamide derivatives |
| AU1328197A (en) | 1995-12-01 | 1997-06-19 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
| JP2000507544A (ja) | 1996-03-25 | 2000-06-20 | イーライ・リリー・アンド・カンパニー | 痛みの治療方法 |
| WO1998000124A1 (en) | 1996-06-28 | 1998-01-08 | Ortho Pharmaceutical Corporation | Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration |
| US5753693A (en) | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder |
| EP0915697B1 (en) | 1996-06-28 | 2002-09-18 | Ortho-McNeil Pharmaceutical, Inc. | Anticonvulsant sulfamate derivatives useful in treating obesity |
| US5753694A (en) | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) |
| BR9711151A (pt) | 1996-08-14 | 1999-08-17 | Searle & Co | Forma cristalina de 4-¬5-metil-3-fenilsoxazol-4-il¾benzenossulfonamida |
| EP0942752B1 (en) | 1996-08-23 | 2005-04-20 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
| US20020015713A1 (en) | 1996-10-24 | 2002-02-07 | Murdock Robert W. | Methods and transdermal compositions for pain relief |
| US5935933A (en) | 1997-07-16 | 1999-08-10 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating neuropathic pain |
| US5760007A (en) | 1997-07-16 | 1998-06-02 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating neuropathic pain |
| AU9021298A (en) | 1997-08-15 | 1999-03-08 | Carolyn Ann Fairbanks | Agmatine as a treatment for neuropathic pain |
| GB9803536D0 (en) | 1998-02-19 | 1998-04-15 | Black James Foundation | Histamine H,receptor ligands |
| UA65607C2 (uk) | 1998-03-04 | 2004-04-15 | Орто-Макнейл Фармацевтикал, Інк. | Фармацевтична композиція (варіанти) та спосіб її приготування |
| DK72798A (da) | 1998-05-28 | 1998-05-28 | Novo Nordisk As | Treatment of GABA-uptake related disorders |
| EP1100504A2 (en) | 1998-07-02 | 2001-05-23 | Eisai Co., Ltd. | Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
| US6541520B1 (en) | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| CZ20012620A3 (cs) | 1999-01-19 | 2002-09-11 | Ortho-Mcneil Pharmaceutical, Inc. | Léčivo pro léčení histaminové cefalalgie |
| WO2000042995A2 (en) | 1999-01-21 | 2000-07-27 | Ortho-Mcneil Pharmaceutical, Inc. | Use of anticonvulsant derivatives for treating transformed migraine |
| CA2364949A1 (en) | 1999-02-24 | 2000-08-31 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
| WO2000054588A1 (en) | 1999-03-15 | 2000-09-21 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
| MXPA01010218A (es) | 1999-04-08 | 2002-03-27 | Johnson & Johnson | Derivados anticonvulsivos utiles para disminuir lipidos. |
| NZ514811A (en) | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
| US6583172B1 (en) | 1999-04-08 | 2003-06-24 | Richard P. Shank | Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders |
| CA2369230A1 (en) | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in maintaining weight loss |
| ES2228521T3 (es) | 1999-05-04 | 2005-04-16 | Keith R. Edwards | Valproato intravenoso para el tratamiento agudo de la jaqueca. |
| ES2291215T3 (es) | 1999-06-14 | 2008-03-01 | Vivus, Inc. | Terapia de combinacion para producir perdida de peso y tratar la obesidad. |
| US6562865B1 (en) | 1999-08-20 | 2003-05-13 | Ortho-Mcneil Pharmaceutical, Inc. | Composition comprising a tramadol material and an anticonvulsant drug |
| FR2803848B1 (fr) | 2000-01-19 | 2002-02-15 | Adir | Nouveaux derives de benzenesulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6322503B1 (en) | 2000-02-17 | 2001-11-27 | G. Roger Sparhawk, Jr. | Method of diagnosing, tracking, and treating depression |
| US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| PT1309324E (pt) | 2000-07-07 | 2006-06-30 | Ortho Mcneil Pharm Inc | Derivados de anticonvulsivos uteis para o tratamento e prevencao do desenvolvimento de diabetes mellitus do tipo ii e da sindroma x |
| DE10035227A1 (de) | 2000-07-20 | 2002-01-31 | Solvay Pharm Gmbh | Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind |
| US6946243B2 (en) * | 2000-07-20 | 2005-09-20 | Solvay Pharmaceuticals Gmbh | Method of identifying compounds suitable for treatment and/or prophylaxis of obesity |
| CA2417304A1 (en) | 2000-08-02 | 2002-02-07 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
| US7256184B2 (en) | 2000-10-16 | 2007-08-14 | Rodriguez Victorio C | Treatment of aging disorders in humans |
| EP1357908A4 (en) | 2001-01-30 | 2009-07-15 | Merck & Co Inc | "ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS" |
| CA2448160A1 (en) | 2001-05-25 | 2002-12-05 | Queen's University At Kingston | Heterocyclic beta-amino acids and their use as anti-epileptogenic agents |
| US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
| US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
| RU2246727C2 (ru) | 2003-02-12 | 2005-02-20 | Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева (НИПИ) | Способ диагностики доклинической стадии эпилепсии |
| RU2226357C1 (ru) | 2003-02-12 | 2004-04-10 | Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М.Бехтерева | Способ диагностики эпилепсии у пациентов с доклинической стадией болезни |
| AU2004231070B2 (en) | 2003-04-10 | 2008-02-14 | Amgen, Inc. | Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof |
| ES2322451T3 (es) | 2003-04-16 | 2009-06-22 | Smithkline Beecham Corporation | Inhibidores de la peptido deformilasa. |
| JPWO2004093912A1 (ja) | 2003-04-23 | 2006-07-13 | 協和醗酵工業株式会社 | 好中球性炎症疾患の予防および／または治療剤 |
| GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
| US6949518B1 (en) | 2003-06-25 | 2005-09-27 | Pao-Hsien Chu | Methods for treating macular degeneration with topiramate |
| EP1664011A4 (en) | 2003-09-02 | 2009-02-25 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| AR049646A1 (es) | 2004-06-16 | 2006-08-23 | Janssen Pharmaceutica Nv | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| WO2006010008A1 (en) | 2004-06-22 | 2006-01-26 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives for modulation of calcium channels |
| EP1781639B1 (en) | 2004-07-28 | 2012-01-25 | Janssen Pharmaceutica NV | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| MX2007002309A (es) | 2004-08-24 | 2007-10-08 | Johnson & Johnson | Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos. |
| US20060276528A1 (en) | 2004-08-24 | 2006-12-07 | Abdel-Magid Ahmed F | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
| KR20080009295A (ko) | 2005-04-22 | 2008-01-28 | 와이어쓰 | 벤조디옥산 및 벤조디옥솔란 유도체 및 이의 용도 |
| MX2007014613A (es) | 2005-05-20 | 2008-04-02 | Johnson & Johnson | Procedimiento para la preparacion de derivados de sulfamida. |
| AR058389A1 (es) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
| US20070155824A1 (en) | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis |
| WO2007137167A2 (en) | 2006-05-19 | 2007-11-29 | Janssen Pharmaceutica N.V. | Co-therapy for the treatment of epilepsy |
| US20070293476A1 (en) | 2006-05-19 | 2007-12-20 | Smith-Swintosky Virginia L | Co-therapy for the treatment of epilepsy and related disorders |
| WO2008061903A1 (en) | 2006-11-22 | 2008-05-29 | Agfa Healthcate Inc. | Method and system for client / server distributed image processing |
| WO2009089210A1 (en) | 2008-01-07 | 2009-07-16 | Janssen Pharmaceutica N. V. | Preparation of sulfamide derivatives |
| US20090247618A1 (en) | 2008-03-26 | 2009-10-01 | Ballentine Scott A | Process for preparation of benzo-fused heteroaryl derivatives |
| US20090247617A1 (en) | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
| AU2009271362B2 (en) | 2008-06-23 | 2014-03-13 | Janssen Pharmaceutica Nv | Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
-
2006
- 2006-12-18 AR ARP060105591A patent/AR058389A1/es not_active Application Discontinuation
- 2006-12-18 US US11/611,938 patent/US8492431B2/en not_active Expired - Fee Related
- 2006-12-19 RS RS20110496A patent/RS52044B/sr unknown
- 2006-12-19 PE PE2006001639A patent/PE20070813A1/es not_active Application Discontinuation
- 2006-12-19 AU AU2006331637A patent/AU2006331637B2/en not_active Ceased
- 2006-12-19 BR BRPI0620019-2A patent/BRPI0620019A2/pt not_active IP Right Cessation
- 2006-12-19 MY MYPI20082188A patent/MY145823A/en unknown
- 2006-12-19 KR KR1020087017531A patent/KR101363308B1/ko not_active Expired - Fee Related
- 2006-12-19 PT PT06847860T patent/PT1968574E/pt unknown
- 2006-12-19 SI SI200631151T patent/SI1968574T1/sl unknown
- 2006-12-19 ME MEP-2011-166A patent/ME01344B/me unknown
- 2006-12-19 CN CN2006800524528A patent/CN101365442B/zh not_active Expired - Fee Related
- 2006-12-19 DK DK06847860.1T patent/DK1968574T3/da active
- 2006-12-19 EA EA200870093A patent/EA016560B1/ru not_active IP Right Cessation
- 2006-12-19 CA CA2634093A patent/CA2634093C/en not_active Expired - Fee Related
- 2006-12-19 NZ NZ568960A patent/NZ568960A/en not_active IP Right Cessation
- 2006-12-19 WO PCT/US2006/048681 patent/WO2007075833A2/en not_active Ceased
- 2006-12-19 ES ES06847860T patent/ES2369761T3/es active Active
- 2006-12-19 JP JP2008547519A patent/JP5190378B2/ja not_active Expired - Fee Related
- 2006-12-19 HR HRP20110726TT patent/HRP20110726T2/hr unknown
- 2006-12-19 PL PL06847860T patent/PL1968574T3/pl unknown
- 2006-12-19 AT AT06847860T patent/ATE519484T1/de active
- 2006-12-19 EP EP06847860A patent/EP1968574B9/en active Active
- 2006-12-19 UY UY30033A patent/UY30033A1/es unknown
-
2008
- 2008-06-12 IL IL192107A patent/IL192107A/en not_active IP Right Cessation
- 2008-06-19 SV SV2008002952A patent/SV2008002952A/es unknown
- 2008-07-03 NO NO20083006A patent/NO20083006L/no not_active Application Discontinuation
- 2008-07-18 ZA ZA200806279A patent/ZA200806279B/xx unknown
- 2008-07-21 CR CR10164A patent/CR10164A/es not_active Application Discontinuation
-
2011
- 2011-11-09 CY CY20111101079T patent/CY1112357T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01344B (me) | Upotreba derivata benzo-kondenziranih heterocikličkih sulfamida za liječenje gojaznosti | |
| HRP20100007T1 (hr) | Upotreba benzo-spojenih heterocikličkih derivata sulfamida za liječenje boli | |
| HRP20120018T1 (hr) | Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida kao neurozaštitnih sredstava | |
| HRP20110384T1 (hr) | Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida za liječenje manije i bipolarnog poremećaja | |
| CA2570606A1 (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
| HRP20110008T1 (hr) | Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida za smanjenje razine masnoća i šećera u krvi | |
| JP2009520036A5 (me) | ||
| JP2009520035A5 (me) | ||
| JP2009520030A5 (me) | ||
| BR0116624A (pt) | Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto ou da composição farmacêutica, e, produto de combinação | |
| TW200716595A (en) | Chromane and chromene derivatives and uses thereof | |
| ES2213007T3 (es) | Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2. | |
| PL2176252T3 (pl) | 2,3-dihydrobenzo[1,4]dioksyn-2-ylometylopochodne jako antagoniści receptora alfa2c do zastosowania w leczeniu chorób obwodowego i ośrodkowego układu nerwowego | |
| BR0309106A (pt) | Derivados de terfenila, seu preparo, as composições farmacêuticas que os contêm | |
| RU2007133167A (ru) | Препарат на основе смеси флавоноидов со свободным в-циклом и флаванов, как терапевтический агент | |
| EP2046336A4 (en) | 3-ARYL-6-ARYL-7H- [1,2,4] TRIAZOLO [3,4-B] [1,3,4] THIADIAZINE AND ANALOGUE AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCTORS AND THEIR USE | |
| YU100992A (sh) | Supstituisani fenilfenolni leukotrienski antagonisti | |
| ZA200404544B (en) | Use of endothelin receptor antagonists in the treatment of tumour diseases. | |
| KR880009948A (ko) | 항 알레르기 및 항 염증제로서 용도를 갖는 신규의 나프탈렌 유도체 | |
| DK1311264T3 (da) | Substituerede og usubstituerede benzooxathiaxoler og deres afledte forbindelser | |
| JP2005521705A5 (me) | ||
| RU2013146602A (ru) | Фармацевтическая композиция для лечения болезни печени | |
| BR0004548A (pt) | Derivados i de quinolin-4-ila | |
| PT99673A (pt) | Processo para a preparacao de derivados de 1-piperazino-indano e de composicoes farmaceuticas que os contem | |
| FI951091A0 (fi) | Uudet alkyyliaminoindaaniyhdisteet, menetelmät niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset |